加载中
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
前收盘价
US$9.48
−US$0.20 · -2.07%
盘前
US$8.99
−US$0.49 · -5.17%
10月12日 5:20 ET
盘中时间采用ET。市场数据可能有所延迟。
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
日内区间
当前US$9.48
52周区间
当前US$9.48
盘中时间采用ET。市场数据可能有所延迟。
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
日内区间
当前US$9.48
52周区间
当前US$9.48
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 营收 | 494万 USD | 439.1万 USD | 504.3万 USD | 411.3万 USD |
| 销货成本 | 474万 USD | 450.3万 USD | 735.4万 USD | 910.1万 USD |
| 毛利 | 20万 USD | −11.2万 USD | −231.1万 USD | −498.8万 USD |
| 研究与开发 | 300万 USD | 338万 USD | 221.3万 USD | 190.2万 USD |
| 销售、一般及管理费用 | 1000万 USD | 1022万 USD | 1097.8万 USD | 417.7万 USD |
| 营业费用 | 1300万 USD | 1360万 USD | 1319.1万 USD | 607.9万 USD |
| 利息收入 | — | — | 2000 USD | 9000 USD |
| 利息支出 | — | 306.7万 USD | 14万 USD | 5000 USD |
| 折旧和摊销 | 51.2万 USD | 54.3万 USD | 58.5万 USD | 54.5万 USD |
| 营业利润 | −1280万 USD | −1371.2万 USD | −1550.2万 USD | −1106.7万 USD |
| 净利润 | −2700万 USD | −2105.5万 USD | −1556.9万 USD | −1116.8万 USD |
公司数据更新于 2026年10月12日。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
